Skin Cancer

Conference Insider
Cosibelimab Safe, Clinically Active in Patients With mCSCC
09/19/2020
Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.
Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.
Preliminary safety and efficacy...
09/19/2020
Oncology
Experts Seek to Establish Adjuvant Role of Cemiplimab in Treatment of CSCC
Videos
Experts Seek to Establish Adjuvant Role of Cemiplimab in Treatment of CSCC
06/05/2020
Danny Rischin, MBBS, FRACP, MD, discusses the clinical importance of a phase 3 clinical trial evaluating adjuvant cemiplimab in patients with high-risk CSCC.
Danny Rischin, MBBS, FRACP, MD, discusses the clinical importance of a phase 3 clinical trial evaluating adjuvant cemiplimab in patients with high-risk CSCC.
Danny Rischin, MBBS, FRACP, MD,...
06/05/2020
Oncology
Few Side Effects With Intrathecal vs Systemic Nivolumab for Metastatic Melanoma and Brain Tumors
Videos
Few Side Effects With Intrathecal vs Systemic Nivolumab for Metastatic Melanoma and Brain Tumors
06/01/2020
Claire Verschraegen, MD, discusses a study of toxicities associated with the use of intrathecally-injected nivolumab in patients with metastatic melanoma who have leptomeningeal disease.
Claire Verschraegen, MD, discusses a study of toxicities associated with the use of intrathecally-injected nivolumab in patients with metastatic melanoma who have leptomeningeal disease.
Claire Verschraegen, MD,...
06/01/2020
Oncology
Cemiplimab Yields High Rate of Durable Responses in Advanced CSCC
Videos
Cemiplimab Yields High Rate of Durable Responses in Advanced CSCC
05/31/2020
Danny Rischin, MBBS, FRACP, MD, discusses a phase 2 clinical trial in which cemiplimab was shown to yield high rates of long-term response in patients with advanced CSCC.
Danny Rischin, MBBS, FRACP, MD, discusses a phase 2 clinical trial in which cemiplimab was shown to yield high rates of long-term response in patients with advanced CSCC.
Danny Rischin, MBBS, FRACP, MD,...
05/31/2020
Oncology
News
Nivolumab Plus Ipilimumab Extends TFS Over Nivolumab Alone in Advanced Melanoma
05/31/2020
With extended follow-up, patients with advanced melanoma given nivolumab plus ipilimumab were shown to have a TFS twice as long as those given nivolumab alone.
With extended follow-up, patients with advanced melanoma given nivolumab plus ipilimumab were shown to have a TFS twice as long as those given nivolumab alone.
With extended follow-up,...
05/31/2020
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use